Greylin Investment Mangement Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 2.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 58,388 shares of the biopharmaceutical company’s stock after purchasing an additional 1,440 shares during the quarter. Greylin Investment Mangement Inc.’s holdings in Pfizer were worth $2,115,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in PFE. Mckinley Capital Management LLC Delaware purchased a new position in Pfizer in the second quarter worth $103,000. Herndon Capital Management LLC purchased a new position in Pfizer in the second quarter worth $120,000. Americafirst Capital Management LLC purchased a new position in Pfizer in the third quarter worth $127,000. Oak Point Wealth Management purchased a new position in Pfizer in the fourth quarter worth $165,000. Finally, Lipe & Dalton grew its position in Pfizer by 6.9% in the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 300 shares in the last quarter. 71.41% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director W Don Cornwell sold 1,758 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $36,790. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 185,464 shares of company stock valued at $6,767,939. Insiders own 0.06% of the company’s stock.
Pfizer Inc. (NYSE:PFE) opened at $36.75 on Wednesday. The company has a market cap of $218,770.00, a PE ratio of 21.00, a PEG ratio of 2.07 and a beta of 0.91. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. Pfizer Inc. has a one year low of $31.67 and a one year high of $39.43.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 earnings per share. sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer declared that its board has initiated a share buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s board of directors believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.70%. This is an increase from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend was Thursday, February 1st. Pfizer’s dividend payout ratio is 77.71%.
TRADEMARK VIOLATION WARNING: “Pfizer Inc. (PFE) Shares Bought by Greylin Investment Mangement Inc.” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3260983/pfizer-inc-pfe-shares-bought-by-greylin-investment-mangement-inc.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.